The American Journal of Managed Care

Understanding EGFR Mutations and First-Line Treatment

Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...
European Medical Journal

Osimertinib Plus Chemo Extends Survival in EGFR-Mutated NSCLC

In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy ...
PharmiWeb

Subcutaneous RYBREVANT® (amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...